Literature DB >> 31086328

Walking over the inflammasome.

Oliver Gorka1, Emilia Neuwirt1, Olaf Groß2,3.   

Abstract

Mesh:

Substances:

Year:  2019        PMID: 31086328     DOI: 10.1038/s41589-019-0292-8

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN: 1552-4450            Impact factor:   15.040


× No keyword cloud information.
  3 in total

1.  Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors.

Authors:  D G Perregaux; P McNiff; R Laliberte; N Hawryluk; H Peurano; E Stam; J Eggler; R Griffiths; M A Dombroski; C A Gabel
Journal:  J Pharmacol Exp Ther       Date:  2001-10       Impact factor: 4.030

2.  MCC950 closes the active conformation of NLRP3 to an inactive state.

Authors:  Ana Tapia-Abellán; Diego Angosto-Bazarra; Helios Martínez-Banaclocha; Carlos de Torre-Minguela; Jose P Cerón-Carrasco; Horacio Pérez-Sánchez; Juan I Arostegui; Pablo Pelegrin
Journal:  Nat Chem Biol       Date:  2019-05-13       Impact factor: 15.040

3.  The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction.

Authors:  Gerardus P J van Hout; Lena Bosch; Guilielmus H J M Ellenbroek; Judith J de Haan; Wouter W van Solinge; Matthew A Cooper; Fatih Arslan; Saskia C A de Jager; Avril A B Robertson; Gerard Pasterkamp; Imo E Hoefer
Journal:  Eur Heart J       Date:  2017-03-14       Impact factor: 29.983

  3 in total
  1 in total

1.  In Silico Insights towards the Identification of NLRP3 Druggable Hot Spots.

Authors:  Nedra Mekni; Maria De Rosa; Chiara Cipollina; Maria Rita Gulotta; Giada De Simone; Jessica Lombino; Alessandro Padova; Ugo Perricone
Journal:  Int J Mol Sci       Date:  2019-10-09       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.